Panstay-DSR Composition and Introduction

Panstay-DSR is a combination of a proton pump inhibitor Pantoprazole 40mg along with an anti-emetic Domperidone 30mg. Both are combined efficiently to provide relief from hyperacidity to the patient suffering from the same along with the related symptoms in a manner; referred to as Sustained release, that once daily dose is able to provide needed relief to the patient. It is marketed by Brenstem Biosciences. 

It is a combination of pantoprazole and domperidone. Pantoprazole is a potent proton pump inhibitor. It inhibits the H + /K + - ATPase enzyme (proton pump) irreversibly and blocks the final step of acid secretion. Domperidone is a potent dopamine receptor (D2) antagonist. It increases motility of GI tract by inhibiting the action of dopamine and fastens gastric emptying. Domperidone increases Lower esophageal sphincter pressure and prevent reflux of stomach content into esophagus. Domperidone also inhibits the D2 receptor in the chemoreceptor trigger zone thereby it prevents nausea and vomiting.


Comments

Post a Comment

Popular posts from this blog

Panstay-DSR (Rationale of Combination)

Powerful synergistic combination for faster healing GERD and erosive esophagitis. Rapid and lasting reduction in acid production. Increases lower esophageal tone and esophageal clearance. Round the clock relief from GERD in lower dose due to sustained release dosage form. Convenience once daily dose increases compliance. More effective in 24-hour intragastric pH profiles than Omeprazole. Low potential to interact with the cytochrome P450 enzyme system. Steady state serum concentration.
Read more

Panstay-DSR: Undesirable effects

1) Very rarely extrapyramidal syndrome - e.g. Parkinsonism, tardive dyskinesia. 2) Domperidone may cause galactorrhoea and gynaecomastia due to                                     Hyperprolactinaemia 3) Other minor side effects Dry mouth, thirst Headache Nervousness Diarrhea Skin rash, itching Increase in TSH level, hypothyroid woman.
Read more